Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy

Inoue, Maiko; Arakawa, Akira; Yamane, Shin; Kadonosono, Kazuaki

doi:10.1038/eye.2013.179

Cited by 31 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study of anti-VEGF with PDT also included a small case series and reported results similar to those of our study [8–12], and in the treatment of PCV, the long-term outcome of anti-VEGF therapy with PDT is less positive than that of anti-VEGF monotherapy [39]. Long-time observation would be needed.…”

Section: Discussionsupporting

confidence: 81%

Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study

et al. 2017

View full text Add to dashboard Cite

Polypoidal choroidal vasculopathy (PCV) is characterized by polyp-like choroidal neovascularization and a branching vascular network. Intravitreal aflibercept injection (IAI) or photodynamic therapy (PDT) is used for treatment. We retrospectively compared the 1-year outcomes of IAI monotherapy and its combination with initial PDT for PCV. Twelve eyes with naïve PCV received three IAIs and a single PDT after the first IAI and as needed injection (combination group); 11 eyes with naïve PCV received three IAIs and as needed injections (IAI group). Significant improvements in visual acuity after 2 months and in CRT after 1 month were maintained at 12 months in both groups (both P < 0.05); groups did not differ significantly at any time point. CCT significantly reduced after 3 and 12 months in the combination group (both P < 0.05) but not in the IAI group. A mean of 3.7 ± 0.9 and 5.6 ± 2.0 injections was administered to the combination and IAI groups, respectively (P = 0.013). Within a 1-year period, combination therapy was found to yield similar visual acuity and retinal structure improvements and maintenance as IAI monotherapy while requiring fewer IAIs.

show abstract

Section: Discussionsupporting

confidence: 81%

Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Several experts group still recommend PDT, with or without anti-VEGF, as the treatment of choice for PCV [14]. However, other investigator groups have demonstrated a comparable or even superior efficacy of anti-VEGF therapy over PDT for treating PCV [19,40]. For this reason, we believe that our treatment method may not have significantly influenced the treatment outcome, despite none of our patients receiving PDT.…”

Section: Discussionmentioning

confidence: 69%

Polypoidal choroidal vasculopathy in patients aged less than 50 years: characteristics and 6-month treatment outcome

Chang

Kim

et al. 2015

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…VEGF is considered to be a potent endothelial cell mitogen that promotes migration, proliferation, and tube formation, leading to angiogenic growth of new blood vessels [22] . Anti-VEGF therapies might be effective treatment options at present [23,24] . However, some clinical reports have shown that anti-VEGF therapy is not effective for all patients, and there is potential toxicity to retinal neurons and glia [25,26] .…”

Section: Discussionmentioning

confidence: 99%

The Suppression of Kallistatin on High-Glucose-Induced Proliferation of Retinal Endothelial Cells in Diabetic Retinopathy

et al. 2016

View full text Add to dashboard Cite

Background: Diabetic retinopathy (DR) is a severe ocular complication of diabetes. Kallistatin has multiple biological functions including anti-inflammation and antiangiogenesis. Our aim was to detect the level of kallistatin in the vitreous of proliferative DR (PDR) and its effect on proliferation, migration, and tube formation of human retinal endothelial cells (HRECs) under high glucose in an in vitro model. Methods: Vitreous humor samples were obtained through pars plana vitrectomy from 7 nondiabetic patients with idiopathic macular holes or idiopathic preretinal membranes and 10 PDR patients. The vitreous levels of kallistatin were measured by ELISA. HRECs were cultured with different concentrations of glucose and 1,000 nM kallistatin. The proliferation of HRECs was evaluated by a Cell Counting Kit-8 assay. Cell migration was assessed by using Transwell chambers. Cell sprouting was detected by tube formation assay. The RNA interference technique was used to create the knockdown of the kallistatin gene in HRECs for evaluating its effect on the proliferation, migration, and tube formation of HRECs. Results: The vitreous levels of kallistatin were significantly lower in PDR patients in comparison with nondiabetic control patients (p < 0.05). Compared with 5 mM of normal glucose treatment, high glucose (30 mM) in culture significantly increased the proliferation and migration of HRECs, which was attenuated by 1,000 nM kallistatin. In addition, 1,000 nM kallistatin was shown to suppress high-glucose-induced tube formation and the expression of vascular endothelial growth factor of HRECs. Furthermore, the knockdown of kallistatin enhanced the proliferation, migration, and tube formation of HRECs. Conclusions: Our data indicated that kallistatin might be a potent inhibitory factor for PDR. The molecule plays its role by inhibiting high-glucose-induced proliferation of HRECs. The findings suggest that the upregulation of kallistatin might be an effective strategy for PDR prevention.

show abstract

Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy

Cited by 31 publications

References 30 publications

Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study

Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study

Polypoidal choroidal vasculopathy in patients aged less than 50 years: characteristics and 6-month treatment outcome

The Suppression of Kallistatin on High-Glucose-Induced Proliferation of Retinal Endothelial Cells in Diabetic Retinopathy

Contact Info

Product

Resources

About